Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QLS31905 plus chemotherapy ± QL2107 in CLDN18.2-positive advanced biliary tract cancer
CTR20253464Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QLS-31905 in biliary cancer, sponsored by Qilu Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
QLS-31905
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20253464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253464.